IPO registrations (S-1, F-1) · Registrants
OKYO Pharma Ltd
- SEC CIK
- 1849296 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2022-03-04, last 2023-06-09; 3 initial registrations, 14 amendments
- Outcome
- Final prospectus filed 2022-05-18; declared effective 2022-05-16; withdrawal requested 2023-01-12
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Business address
- 55 PARK LANE, London, X0 W1K 1NA
- Ticker
- OKYO (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- OKYO Pharma Ltd on the corporate pages
Offering terms
- Final price
- $4.00 per ADS (424B4 filed 2022-05-18, an initial public offering)
- Shares sold
- 625,000
- Gross proceeds
- $2,500,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol OKYO
- Lead underwriters
- ThinkEquity
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: OKYO Pharma Ltd EXACT (CIK (EXACT))
Filings 26
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2022-03-04 | F-1 | F-1 (foreign registration) | OKYO Pharma Ltd | 0001493152-22-006119 ↗ |
| 2022-03-25 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-22-007784 ↗ |
| 2022-04-14 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-22-009957 ↗ |
| 2022-04-26 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-22-011214 ↗ |
| 2022-05-04 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-22-011966 ↗ |
| 2022-05-09 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-22-012479 ↗ |
| 2022-05-13 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-22-013301 ↗ |
| 2022-05-16 | EFFECT | EFFECT (declared effective) | OKYO Pharma Ltd | 9999999995-22-001489 ↗ |
| 2022-05-16 | EFFECT | EFFECT (declared effective) | OKYO Pharma Ltd | 9999999995-22-001496 ↗ |
| 2022-05-18 | 424B4 | 424B4 (final prospectus) | OKYO Pharma Ltd | 0001493152-22-014266 ↗ |
| 2022-12-05 | F-1 | F-1 (foreign registration) | OKYO Pharma Ltd | 0001493152-22-034473 ↗ |
| 2022-12-09 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-22-034990 ↗ |
| 2023-01-03 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-23-000158 ↗ |
| 2023-01-12 | RW | RW (withdrawal request) | OKYO Pharma Ltd | 0001493152-23-001282 ↗ |
| 2023-01-19 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-23-001850 ↗ |
| 2023-02-17 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-23-005437 ↗ |
| 2023-02-22 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-23-005751 ↗ |
| 2023-02-27 | EFFECT | EFFECT (declared effective) | OKYO Pharma Ltd | 9999999995-23-000488 ↗ |
| 2023-03-08 | EFFECT | EFFECT (declared effective) | OKYO Pharma Ltd | 9999999995-23-000543 ↗ |
| 2023-03-14 | 424B4 | 424B4 (final prospectus) | OKYO Pharma Ltd | 0001493152-23-007596 ↗ |
| 2023-05-17 | F-1 | F-1 (foreign registration) | OKYO Pharma Ltd | 0001493152-23-017939 ↗ |
| 2023-06-02 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-23-020034 ↗ |
| 2023-06-08 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-23-020572 ↗ |
| 2023-06-09 | F-1/A | F-1/A (amendment) | OKYO Pharma Ltd | 0001493152-23-020718 ↗ |
| 2023-06-14 | EFFECT | EFFECT (declared effective) | OKYO Pharma Ltd | 9999999995-23-001750 ↗ |
| 2023-06-14 | EFFECT | EFFECT (declared effective) | OKYO Pharma Ltd | 9999999995-23-001755 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-13 | F-1/A | registration statement | 508,130 | - | Nasdaq OKYO | 1 | primary document; shares headline, cover names 1 | document ↗ | ||
| 2022-05-18 | 424B4 | final prospectus | $4.00 | 625,000 | $2,500,000 | Nasdaq OKYO | 1 | primary document; price sentence, shares headline, proceeds table, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BRANCACCIO JOHN P | Director | 6 | 2022–2026 | ||
| CERRONE GABRIELE M | Director,Officer; Director,Officer,TenPercentOwner; Director,TenPercentOwner | Executive Chairman; Non-Executive Chairman | 12 | 2022–2026 | |
| Denoyer Bernard | Director | 3 | 2022–2026 | ||
| JACOB GARY S | Director,Officer | Chief Development Officer; CHIEF DEVELOPMENT OFFICER; Chief Executive Officer | 5 | 2022–2026 | |
| Shah Keeren | Officer | Chief Financial Officer | 1 | 2022 | |
| Simon Willy Jules | Director | 3 | 2022–2026 | ||
| Dempsey Robert John | Director,Officer | CHIEF EXECUTIVE OFFICER | 3 | 2026 | |
| Shah Keeren Rameshchandra | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 2 | 2026 | |
| Mantelli Flavio | Officer | CHIEF MEDICAL OFFICER | 3 | 2026 | |
| Patil Rajkumar V. | Officer | Chief Scientific Officer | 3 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | OKYO Pharma Ltd | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), X0 first:
- Abcam plc X0
- Immunocore Holdings plc X0
- Autolus Therapeutics plc X0
- Orchard Therapeutics plc X0
- Freeline Therapeutics Holdings plc X0
- Achilles Therapeutics plc X0
- Gyroscope Therapeutics Holdings plc X0
- Exscientia plc X0
- TC BioPharm (Holdings) plc X0
- BioNTech SE 2M
In other datasets, the same topic (Health) in X0:
- Form D issuer: Abcam plc (Form D private offerings)
Interests: Biological Products, (No Diagnostic Substances) · Health